Monthly Archives: January 2011

Former EMA Head Back in the Regulatory Saddle

By Julian Upton | Published: January 17, 2011
His decade-long tenure as head of the European Medicines Agency (EMA) may have ended, but Thomas Lönngren is already back in the regulatory saddle as a strategic advisor to NDA Group, an independent consulting group focused on reducing wasted drug development costs, ensuring new medicines get to market faster, and “improving the performance of the [...]
Posted in Europe, Global, Market Access, People, R&D, Regulatory, leadership, pricing | Tagged , , , , | Leave a comment

Online Physician Communities: Know Your Network

By Guest Blogger | Published: January 12, 2011
Online physician communities are like sweet shops for brand managers. Or are they? asks Jacky Law. For as long as pharma has been around, it has been trying to engage with doctors. Recently, that has meant following them onto the web into a range of physician-only communities. These cater, at one end of the spectrum, for large [...]
Posted in Technology, social media | Tagged , , , , | 3 Comments

New Decade, New Agenda for Pharma

By Guest Blogger | Published: January 12, 2011
A new track for nonprofits, product diversification and the rise of the emerging markets —  Audrey S. Erbes reports on some of the takeaways from this week’s JP Morgan Healthcare Conference. There were some surprising changes in the format of the 29th Annual JP Morgan Healthcare Conference, the world’s premier health care industry investment meeting which [...]
Posted in Emerging Markets, Guest Blog, R&D | Tagged , , , , , | Leave a comment

Tufts R&D Outlook for 2011: Pain Mixed with Promise

By William Looney | Published: January 12, 2011
The Tufts Center for Drug Development issues its annual assessment of the state of R&D in Big Pharma, noting that industry faces a cumulative tide of challenges marked by a dramatic reversal in societal attitudes toward risk. Productivity gaps in the pipeline aside, perhaps the biggest problem is political — convincing stakeholders to strive for [...]
Posted in FDA, Gene therapy, R&D, Regulatory | Tagged , , , , , , | 1 Comment

Medicines Malaise: Sanofi's Fresh Bet on Patient Centric R&D

By William Looney | Published: January 12, 2011
With a new R&D structure and a high profile appointment to lead it, Sanofi is bidding for leadership in that “new model” the industry is seeking to replenish its anemic pipeline of new products Reinvigorating the productive capacity of in-house R&D is the most prominent strategic challenge confronting big Pharma.  There are many options but few [...]
Posted in R&D, Strategy | Tagged , , | Leave a comment